SavedAdd your journal

Journals / MN Kardiyoloji / 2015 / Cilt: 22 - Sayı: 1

Drug Eluting Coronary Stents

İlaç Salınımlı Koroner Stentler

Veysel Özgür BARIŞ
Demet GEREDE MENEKŞE
Deniz KUMBASAR
Çetin EROL
Pages
53–58
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this paper, the structure of drug eluting stents, comparative studies and the recommendations mentioned in the guidelines are revised.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Coronary artery disease is the most common cause of death today, every day new technologies are introduced in order to prevent this disease and avoid negative consequences.
📊
Key Findings & Data:Drug eluting stents are technologies that proven in various studies reduced in stent restenosis compared to bare metal stents in coronary artery disease.
💡
Conclusion & Impact:In this paper, the structure of drug eluting stents, comparative studies and the recommendations mentioned in the guidelines are revised.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Coronary artery disease is the most common cause of death today, every day new technologies are introduced in order to prevent this disease and avoid negative consequences. Drug eluting stents are technologies that proven in various studies reduced in stent restenosis compared to bare metal stents in coronary artery disease. In this paper, the structure of drug eluting stents, comparative studies and the recommendations mentioned in the guidelines are revised.

Özet

Koroner arter hastalığı günümüzde ölümlerin en sık nedeni olup, bu hastalığı önlemek ve olumsuz sonuçlarının önüne geçmek için her geçen gün yeni teknolojiler piyasaya sürülmektedir. İlaç salınımlı stent teknolojisinin, koroner arter hastalığında çıplak metal stentlere göre stent içi restenozu azalttığı çeşitli çalışmalarda gösterilmiştir. Bu yazıda ilaç salınımlı stentlerin genel yapısı, karşılaştırmalı çalışmaları ve kılavuz önerileri gözden geçirilmektedir.

🔖

Cite This Article

BARIŞ, V. Ö., MENEKŞE, D. G., KUMBASAR, D., EROL, Ç. (2015). Drug Eluting Coronary Stents. MN Kardiyoloji, Cilt: 22 - Sayı: 1, 53–58. https://ajindex.com/articles/297289

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L.Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316:701-6
  2. Serruys PW, Unger F, Sousa JE, et al. Comparison of coro- nary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001;344 (15):1117- 24
  3. Morice MC, Serruys PW, Sousa JE, et al. A randomized com- parison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346:1773-80
  4. Morice MC, Serruys PW, Sousa JE, et al. A polymer-based, paclitaxel-eluting stent inpatients with coronary artery dis- ease. N Engl J Med 2004;350:221-31
  5. K Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) trial. Circulation 2001;103:2816-21
  6. Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011;123:1400-9
  7. Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity earlyin high-risk interventional settings isdriven by stent design and deploymentand protected by polymer-drug coatings. Circulation 2011;123:1400-9. 8. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Mar ked inflammatory sequelae to implantation of bio deg radable- and nonbiodegradable polymers in porci ne coronary arter- ies. Circulation 1996;94:1690-7
  8. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clini- cal outcomes of biodegradablepolymer biolimus-eluting stents versus durable polymer sirolimuselutingstents in pa- tients with coronary artery disease (LEADERS): 4 year fol- lowup of a randomised non-inferiority trial. Lancet 2011;378:1940-8
  9. Ertaş G. Beusekom VH. Anadolu Kardiyol Derg 2012;12 (8):676-83
  10. Stefanini GG. Holmes DR. Drug-Eluting Coronary-Artery Stents. N Engl J Med 2013;368:254-65
  11. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202
  12. Räber L, Baumgartner S, Garcia-Garcia HM, et al. Long- term vascular healing in response to sirolimus- and pacli- taxel-eluting stents: an optical coherence tomography study. JACC Cardiovasc Interv 2012;5:946-57
  13. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary